1Departments of Radiology and Hematology-Oncology, Beaumont Hospital Dearborn, 18101 Oakwood Blvd, Dearborn, MI 48124
American Journal of Medical Case Reports.
2021,
Vol. 9 No. 12, 719-721
DOI: 10.12691/ajmcr-9-12-15
Copyright © 2021 Science and Education PublishingCite this paper: Kara L Heuvelhorst, Tyler Diener, Hana Manzoor, Maher Khadra, Faisal Musa, Syed K Jafri. Cerebral Venous Sinus Thrombosis without Thrombotic Thrombocytopenic Syndrome in a Male Patient after Ad26.COV2.S Vaccination.
American Journal of Medical Case Reports. 2021; 9(12):719-721. doi: 10.12691/ajmcr-9-12-15.
Correspondence to: Hana Manzoor, Departments of Radiology and Hematology-Oncology, Beaumont Hospital Dearborn, 18101 Oakwood Blvd, Dearborn, MI 48124. Email:
hana.manzoor@beaumont.orgAbstract
Objective: Here we present one of the first cases of Janssen (Johnson & Johnson Ad26.COV2.S vaccine-associated cerebral venous sinus thrombosis (CVST) in a male patient, and the presumed first case without associated thrombotic thrombocytopenic syndrome (TTS). Method: Patient was identified as a vaccine-related adverse effect due to the unusual presentation of CVST in a male following COVID-19 vaccination, though without thrombocytopenia. Results: Patient presented with left-sided weakness and transient dysarthria. Imaging revealed extensive CVST. Thorough coagulopathy work-up was negative and platelet levels remained within the normal range. Patient improved with non-heparin anticoagulation. Discussion: As more people worldwide continue to be vaccinated against COVID-19, the incidence of vaccine-related complications can be expected to rise. Multiple cases of CVST have been reported in patients following COVID-19 vaccination with associated TTS, nearly all in women. However, this is not the only presentation. Cerebral venous sinus thrombosis should be a consideration in patients who present with headache or altered mental status after COVID vaccination, despite normal platelet levels.
Keywords
Cerebral Venous Sinus Thrombosis,
Vaccine,
Johnson & Johnson,
Janssen,
AstraZeneca,
Clot,
COVID-19,
FDA,
CDC,
anti-PF4,
Thrombotic Thrombocytopenic Syndrome,
Ad26.COV2.S